Clinical Study

In Vivo Corneal Confocal Microscopy Detects Improvement of Corneal Nerve Parameters following Glycemic Control in Patients with Type 2 Diabetes

Table 2

Clinical characteristics of patients with type 2 diabetes with improved HbA1c at one-year follow-up (group A) and consistently poor glycemic control at one-year follow-up (group B).

ParameterBaselineOne-year follow-up value
Group A0 ()Group B0 ()Group A1 ()Group B1 ()A0 versus B0A1 versus A0B1 versus B0

Age, y56.1 ± 17.559.4 ± 11.57.3 ± 17.460.8 ± 11.10.521≤0.001≤0.001
Sex (M/F)9/79/7
Duration of diabetes, y11.3 ± 11.110.4 ± 7.512.6 ± 10.911.5 ± 7.30.780≤0.001≤0.001
Weight, kg72.0 ± 19.069.8 ± 15.770.3 ± 16.268.9 ± 14.10.2330.2010.940
BMI, kg/m227.36 ± 5.4924.12 ± 7.6926.73 ± 4.5024.10 ± 3.250.0630.2070.909
SBP, mmHg135.6 ± 15.4137.4 ± 17.2134.9 ± 13.5134.8 ± 15.40.3070.8670.059
DBP, mmHg82.7 ± 9.382.5 ± 8.681.4 ± 11.382.2 ± 10.80.8460.5520.486
TC, mmol/L4.46 ± 1.234.51 ± 1.074.44 ± 1.154.54 ± 1.110.8960.9540.208
TG, mmol/L1.83 ± 1.931.92 ± 1.711.31 ± 1.161.74 ± 1.470.6710.1900.367
LDLC, mmol/L2.55 ± 0.782.70 ± 0.732.45 ± 0.802.54 ± 0.800.4240.7390.677
HDLC, mmol/L1.26 ± 0.341.21 ± 0.311.39 ± 0.331.29 ± 0.300.9960.0730.491
HbA1c, %7.78 ± 1.628.55 ± 1.576.52 ± 0.598.79 ± 1.050.2680.0050.527
TCSS4.4 ± 4.46.1 ± 4.54.5 ± 4.86.3 ± 4.70.2930.5440.468
PMNCV, m/s44.47 ± 4.1044.62 ± 4.1544.46 ± 4.3343.39 ± 3.840.8950.9840.124
TMNCV, m/s44.15 ± 4.8644.12 ± 4.3543.56 ± 4.8642.54 ± 4.660.7930.2690.951
SPSNCV, m/s50.42 ± 6.8148.66 ± 7.4850.14 ± 7.1946.64 ± 7.210.2610.2870.056
SSNCV, m/s48.87 ± 7.8947.93 ± 7.2047.28 ± 6.0544.67 ± 6.430.9820.2930.024
CNFD, n/mm218.55 ± 5.2517.19 ± 5.3121.78 ± 6.1315.67 ± 4.160.0700.0050.001
CNBD, n/mm221.76 ± 16.1019.33 ± 12.8226.19 ± 13.8714.23 ± 6.560.3490.1220.033
CNFL, mm/mm211.62 ± 2.8911.16 ± 2.5713.04 ± 2.449.90 ± 1.750.1370.0290.011

Results are expressed as mean ± SD or counts for categorical variables. Independent-sample -test. Paired-sample -test. test.